LIXTE BIOTECHNOLOGY HOLDINGS, INC. Quarterly Share-based Payment Arrangement, Expense in USD from Q3 2015 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Lixte Biotechnology Holdings, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q3 2015 to Q4 2024.
  • Lixte Biotechnology Holdings, Inc. Share-based Payment Arrangement, Expense for the quarter ending December 31, 2024 was $78K, a 25.1% decline year-over-year.
  • Lixte Biotechnology Holdings, Inc. Share-based Payment Arrangement, Expense for the twelve months ending December 31, 2024 was $418K, a 45.9% decline year-over-year.
  • Lixte Biotechnology Holdings, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $418K, a 45.9% decline from 2023.
  • Lixte Biotechnology Holdings, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $773K, a 50% decline from 2022.
  • Lixte Biotechnology Holdings, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $1.55M, a 29.8% decline from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 $418K $78K -$26.1K -25.1% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-24
Q3 2024 $445K $107K -$5.28K -4.71% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 $450K $131K -$149K -53.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $599K $103K -$174K -62.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $773K $104K -$281K -73% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-24
Q3 2023 $1.05M $112K -$285K -71.8% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $1.34M $280K -$144K -34% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $1.48M $277K -$62.7K -18.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $1.55M $385K +$249K +182% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-19
Q3 2022 $1.3M $397K +$49.7K +14.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $1.25M $424K -$637K -60% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $1.88M $340K -$316K -48.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $2.2M $137K +$175K Oct 1, 2021 Dec 31, 2021 10-K 2023-03-29
Q3 2021 $2.03M $347K -$117K -25.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $2.14M $1.06M +$1.03M +3830% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-10
Q1 2021 $1.11M $656K +$629K +2330% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-11
Q4 2020 $481K -$37.8K -$64.8K -240% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-21
Q3 2020 $545K $464K +$432K +1350% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $113K $27K -$297K -91.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 $410K $27K -$12.9K -32.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-12
Q4 2019 $423K $27K -$22.2K -45.1% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-26
Q3 2019 $445K $32K -$752K -95.9% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-10
Q2 2019 $1.2M $324K +$324K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $874K $39.9K +$39.9K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 $834K $49.2K +$16.2K +49.2% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-25
Q3 2018 $817K $784K +$768K +4815% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 $49K $0 +$50.2K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 -$1.24K $0 -$71.9K -100% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $70.7K $33K +$40K Oct 1, 2017 Dec 31, 2017 10-K 2019-03-25
Q3 2017 $30.7K $16K -$130K -89.1% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 $161K -$50.2K -$229K -128% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 $389K $71.9K +$102K Jan 1, 2017 Mar 31, 2017 10-Q 2018-04-27
Q4 2016 $287K -$6.97K Oct 1, 2016 Dec 31, 2016 10-K 2018-03-23
Q3 2016 $146K -$112K -43.4% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-09
Q2 2016 $179K Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-04
Q1 2016 -$30.4K Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q3 2015 $258K Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-04
* An asterisk sign (*) next to the value indicates that the value is likely invalid.